Skip to main content
. 2019 Mar 27;18(3):e12946. doi: 10.1111/acel.12946

Figure 5.

Figure 5

Caspase‐11 is required for immune surveillance of senescent cells in vivo. (a–d) Representative images (a, c) and quantification (b, d) of caspase‐11 (green) and NRAS (magenta) staining in individual liver cells 6 days after hydrodynamic tail vein injection of NRAS with control‐ (a, b) or Casp11‐targeted (c, d) shRNA constructs. White arrows indicate NRAS + ve/caspase‐11 −ve cells (c). (e) qPCR data showing the level of Casp11 expression in livers 3 days after injection of constructs as indicated. (f, g) Representative images (f) and quantification (g) of NRAS staining (brown) in livers after the time and injection of constructs as indicated. (h) Quantification of F4/80 staining in livers treated as indicated. (i) Quantification of number of Ki67/NRAS double +ve cells in livers 6 days after injection of constructs. Data represent mean ± SEM of n = 5 (b, d, e, h, i), or as indicated (g); p = *≤0.05, **≤0.01, ****≤0.0001; ns = not significant. Scale bars = 50 μm (a, c), 300µm (f)